Adenosine A2A receptor (ADORA2A); phosphodiesterase-2 (PDE-2); PDE-3; PDE-4; PDE-7 BriefCommunication Pages: 517 - 517
Notch homolog 1 translocation-associated (NOTCH1); Notch homolog 2 (NOTCH2) BriefCommunication Pages: 518 - 518
Phosphatase and tensin homolog deleted on chromosome ten (PTEN; MMAC1; TEP1) BriefCommunication Pages: 519 - 519
Leukotriene B4 (LTB4); leukotriene B4 type 1 receptor (LTB4R; BLT1); leukotriene B4 type 2 receptor (LTB4R2; BLT2) BriefCommunication Pages: 523 - 523
Brain-derived neurotrophic factor (BDNF); methyl CpG binding protein 2 (MECP2) BriefCommunication Pages: 530 - 530
N-acetyltransferase 8 GCN5-related putative (NAT8); solute carrier family 7 cationic amino acid transporter y+ system member 9 (SLC7A9) BriefCommunication Pages: 534 - 534
Integrin α2 (VLA-2; CD49B); notch homolog 1 translocation-associated (NOTCH1); protein tyrosine phosphatase non-receptor type 22 (PTPN22; LYP) BriefCommunication Pages: 535 - 535
Chemical genetic screen for identifying compounds targeting proteins of unknown function BriefCommunication Pages: 536 - 536
Personalized ex vivo culture method for analysis of antitumor treatment BriefCommunication Pages: 537 - 537
Automated control of blood glucose with insulin-glucagon infusion pumps BriefCommunication Pages: 538 - 538
Size-controlled supramolecular gold nanoparticles for targeted photothermal therapy in cancer BriefCommunication Pages: 539 - 539
Biomarkers for responsiveness to melphalan plus dexamethasone in patients with systemic light chain amyloidosis BriefCommunication Pages: 540 - 540
Leucine-rich repeats and death domain containing (LRDD; PIDD) as a biomarker for resistance to platinum chemotherapy in non–small cell lung cancer (NSCLC) BriefCommunication Pages: 541 - 541
RAD51 homolog C (RAD51C) as a marker for Fanconi anemia and for co-occurring breast and ovarian cancers BriefCommunication Pages: 542 - 542